Expression of TGFβ type‐II receptor in association with markers of proliferation and apoptosis in premalignant lung lesions

Analysis of the early molecular abnormalities that play an oncogenic role in the progression of pulmonary neoplasia may lead to the identification of useful markers for early detection and prognosis. In normal squamous epithelium, transforming growth factor β (TGFβ) regulates cell growth and differentiation via specific membranous receptors and intracellular signaling molecules (Smads). The authors previously observed that, in head and neck squamous cell carcinoma, the expression of the TGFβ type II receptor (TβR‐II) decreases as tumors become less differentiated and more biologically aggressive.

[1]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[2]  G. Bepler,et al.  MCM2 - a promising marker for premalignant lesions of the lung: a cohort study , 2001, BMC Cancer.

[3]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[4]  Simpson,et al.  Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in‐situ and invasive carcinomas , 2000, Histopathology.

[5]  C. Muro-Cacho,et al.  Transforming growth factor β receptors in verrucous and squamous cell carcinoma , 1999 .

[6]  C. Muro-Cacho,et al.  Expression of Transforming Growth Factor β Type II Receptors in Head and Neck Squamous Cell Carcinoma , 1999 .

[7]  J. Minna,et al.  Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. , 1999, Cancer research.

[8]  C. Muro-Cacho,et al.  Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  C. Muro-Cacho,et al.  Transforming growth factor beta receptors in verrucous and squamous cell carcinoma. , 1999, Archives of otolaryngology--head & neck surgery.

[10]  B. Werness,et al.  HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[11]  M. Sporn,et al.  Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Spang‐Thomsen,et al.  Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. , 1994, British Journal of Cancer.

[13]  M. Spang‐Thomsen,et al.  Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. , 1993, British Journal of Cancer.

[14]  M. Sporn,et al.  Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. , 1992, The Journal of biological chemistry.

[15]  G. Serrero,et al.  Decreased transforming growth factor‐(β) response and binding in insulin‐independent teratoma‐derived cell lines with increased tumorigenic properties , 1991, Journal of cellular physiology.

[16]  M. Sporn,et al.  Type beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.